Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Persistence of Engerix-B Antibodies in Adolescents
NCT00343915Phase 3Completed
- Sponsor
- GSK
- Start
- Apr 2004
- Primary completion
- Jan 2008
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 3
01
Overview
Phase 3, open-label trial of hepatitis b vaccine recombinant in hepatitis B (HBV) (2 arms), sponsored by GSK. Primary endpoints: Number of Subjects Seroprotected for Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody at Month 66 and Antibody Titers Against Hepatitis-B Virus at Month 66. Started Apr 2004; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00343915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00343915.